Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression : Focus on the Role of Performance Status
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG..
BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy and ICI plus chemotherapy are approved first-line treatments for patients with non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death-ligand 1 (PD-L1). However, appropriate treatment for patients showing high PD-L1 expression and poor performance status (PS) is not well defined.
OBJECTIVE: The aim of this study was to identify a treatment option that is better for these patients in a real-world setting.
PATIENTS AND METHODS: A total of 425 patients with NSCLC and high PD-L1 expression were included retrospectively. All patients received either pembrolizumab monotherapy or ICI plus chemotherapy as the first-line treatment. Patients were subdivided into good (PS score 0 or 1; n = 354) and poor PS groups (PS score 2 or 3; n = 71). Early progressive disease (PD) was defined as PD within 3 months of ICI-based therapy initiation.
RESULTS: The good PS group had significantly longer progression-free survival (PFS) and overall survival (OS) than the poor PS group upon ICI-based therapy administration. In the poor PS group, no significant difference was observed in PFS and OS between pembrolizumab monotherapy and ICI plus chemotherapy. In the good PS group, pembrolizumab monotherapy, PD-L1 50-89%, and liver metastasis were associated with early PD, as determined using multivariate logistic regression analyses. However, in the poor PS group, the multivariate logistic regression analyses did not show an association between pembrolizumab monotherapy and early PD.
CONCLUSIONS: In patients with NSCLC exhibiting poor PS and high PD-L1 expression, ICI plus chemotherapy did not confer PFS or OS benefit compared with pembrolizumab monotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Targeted oncology - 18(2023), 6 vom: 30. Nov., Seite 915-925 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morimoto, Kenji [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents, Immunological |
|---|
| Anmerkungen: |
Date Completed 30.11.2023 Date Revised 30.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11523-023-01012-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363949062 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363949062 | ||
| 003 | DE-627 | ||
| 005 | 20231226094426.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11523-023-01012-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1213.xml |
| 035 | |a (DE-627)NLM363949062 | ||
| 035 | |a (NLM)37902896 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morimoto, Kenji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression |b Focus on the Role of Performance Status |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2023 | ||
| 500 | |a Date Revised 30.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. | ||
| 520 | |a BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy and ICI plus chemotherapy are approved first-line treatments for patients with non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death-ligand 1 (PD-L1). However, appropriate treatment for patients showing high PD-L1 expression and poor performance status (PS) is not well defined | ||
| 520 | |a OBJECTIVE: The aim of this study was to identify a treatment option that is better for these patients in a real-world setting | ||
| 520 | |a PATIENTS AND METHODS: A total of 425 patients with NSCLC and high PD-L1 expression were included retrospectively. All patients received either pembrolizumab monotherapy or ICI plus chemotherapy as the first-line treatment. Patients were subdivided into good (PS score 0 or 1; n = 354) and poor PS groups (PS score 2 or 3; n = 71). Early progressive disease (PD) was defined as PD within 3 months of ICI-based therapy initiation | ||
| 520 | |a RESULTS: The good PS group had significantly longer progression-free survival (PFS) and overall survival (OS) than the poor PS group upon ICI-based therapy administration. In the poor PS group, no significant difference was observed in PFS and OS between pembrolizumab monotherapy and ICI plus chemotherapy. In the good PS group, pembrolizumab monotherapy, PD-L1 50-89%, and liver metastasis were associated with early PD, as determined using multivariate logistic regression analyses. However, in the poor PS group, the multivariate logistic regression analyses did not show an association between pembrolizumab monotherapy and early PD | ||
| 520 | |a CONCLUSIONS: In patients with NSCLC exhibiting poor PS and high PD-L1 expression, ICI plus chemotherapy did not confer PFS or OS benefit compared with pembrolizumab monotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 700 | 1 | |a Yamada, Tadaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kawachi, Hayato |e verfasserin |4 aut | |
| 700 | 1 | |a Tamiya, Motohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Negi, Yoshiki |e verfasserin |4 aut | |
| 700 | 1 | |a Goto, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakao, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Shiotsu, Shinsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Tanimura, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Takeda, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Asuka |e verfasserin |4 aut | |
| 700 | 1 | |a Harada, Taishi |e verfasserin |4 aut | |
| 700 | 1 | |a Date, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Chihara, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Isao |e verfasserin |4 aut | |
| 700 | 1 | |a Tamiya, Nobuyo |e verfasserin |4 aut | |
| 700 | 1 | |a Nishioka, Naoya |e verfasserin |4 aut | |
| 700 | 1 | |a Katayama, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasaku, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tokuda, Shinsaku |e verfasserin |4 aut | |
| 700 | 1 | |a Kijima, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Takayama, Koichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Targeted oncology |d 2009 |g 18(2023), 6 vom: 30. Nov., Seite 915-925 |w (DE-627)NLM187616825 |x 1776-260X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:6 |g day:30 |g month:11 |g pages:915-925 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11523-023-01012-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 6 |b 30 |c 11 |h 915-925 | ||